New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Bradford K. Amman net worth and biography

Bradford Amman Biography and Net Worth

CFO of Vivos Therapeutics

Bradford Amman has served as our Chief Financial Officer of since October 2018. From January 2017 to October 2018, Mr. Amman served as the Chief Financial Officer and Chief Operations Officer of InLight Medical, a manufacturer and distributor of medical devices cleared by the FDA for increased circulation and reduced pain. Prior to InLight, from 2010 to 2017, he served as CereScan Corp.’s Chief Financial Officer. CereScan specializes in state-of-the-art functional brain imaging, utilizing a patented process, the latest generation functional imaging SPECT and PET cameras and the industry’s leading brain imaging software to assist in the diagnosis of a magnitude of brain-related conditions and disorders. Mr. Amman served as Chief Financial Officer of LifeVantage Corporation from 2006 to 2010, including during its initial public offering. Mr. Amman holds a Master of Business Administration from the University of Notre Dame and a BS in Accounting from the University of Denver.

What is Bradford K. Amman's net worth?: The estimated net worth of Bradford K. Amman is at least $231.20 as of May 25th, 2021. Mr. Amman owns 80 shares of Vivos Therapeutics stock worth more than $231 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Amman may own. Additionally, Mr. Amman receives a salary of $335,530.00 as CFO at Vivos Therapeutics. Learn More about Bradford K. Amman's net worth.
How old is Bradford K. Amman?: Mr. Amman is currently 62 years old. There are 1 older executives and no younger executives at Vivos Therapeutics. The oldest executive at Vivos Therapeutics is Mr. R. Kirk Huntsman, Co-Founder, Chairman of the Board & CEO, who is 66 years old. Learn More on Bradford K. Amman's age.
What is Bradford K. Amman's salary?: As the CFO of Vivos Therapeutics, Inc., Mr. Amman earns $335,530.00 per year. The highest earning executive at Vivos Therapeutics is Mr. R. Kirk Huntsman, Co-Founder, Chairman of the Board & CEO, who commands a salary of $482,160.00 per year. Learn More on Bradford K. Amman's salary.
How do I contact Bradford K. Amman?: The corporate mailing address for Mr. Amman and other Vivos Therapeutics executives is , , . Vivos Therapeutics can also be reached via phone at 866-908-4867 and via email at [email protected]. Learn More on Bradford K. Amman's contact information.
Has Bradford K. Amman been buying or selling shares of Vivos Therapeutics?: Bradford K. Amman has not been actively trading shares of Vivos Therapeutics during the last quarter. Most recently, on Tuesday, May 25th, Bradford K. Amman bought 40 shares of Vivos Therapeutics stock. The stock was acquired at an average cost of $132.25 per share, with a total value of $5,290.00. Following the completion of the transaction, the chief financial officer now directly owns 80 shares of the company's stock, valued at $10,580. Learn More on Bradford K. Amman's trading history.
Who are Vivos Therapeutics' active insiders?: Vivos Therapeutics' insider roster includes Bradford Amman (CFO), and Ronald Huntsman (CEO). Learn More on Vivos Therapeutics' active insiders.

Bradford K. Amman Insider Trading History at Vivos Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/25/2021	Buy	40	$132.25	$5,290.00	80

Bradford K. Amman Buying and Selling Activity at Vivos Therapeutics

Vivos Therapeutics Company Overview

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Today's Range

Now: $2.93

$2.87

$2.99

50 Day Range

MA: $2.78

$2.29

$4.13

2 Week Range

Now: $2.93

$1.91

$48.79

Volume

18,804 shs

Average Volume

477,744 shs

Market Capitalization

$14.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

7.71

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

From Darwin | Ad